A Phase 2A, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of ES-481 in Adult Patients with Drug Resistant Epilepsy.

Phase 2

Recruiting

• Conditions: Epilepsy; Neurological - Epilepsy

• Registration Number: ACTRN12621000033842
• Lead Sponsor: ES Therapeutics Australia Pty Ltd

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-01-15
• Last Update Posted: 21 February 2022

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

1. The subject/legal guardian must be able to understand and sign the Human Research Ethics Committee-approved written Informed Consent Form (ICF) and privacy language as per national regulations (e.g., HREC and TGA requirement in Australia) prior to any study-related procedures being performed.
2. The subject is a male or female 18 to 70 years of age, inclusive
3. The subject must have a history of drug resistant epilepsy (as per the ILAE definition)
4. The subject must be taking 1 to 4 anti-epileptic drugs (AED) and must be on a stable dose of the AEDs for at least four (4) weeks prior to entering the 28-day screening period
5. If VNS implanted, the stimulation setting must have been stable for at least four weeks prior to entering the 28-day screening period
6. The subject/legal guardian must be able to use the seizure dairy to record seizure throughout the study
7. The subject must experience at least four (4) countable seizures within a 28-day period.
For continued enrollment into Treatment Period 1, each subject will be confirmed to have experienced at least four (4) countable seizures in the 28-day screening period
8. The subject must have interictal epileptiform discharges and/or seizure with an average frequency of approximately one (1) per hour on EEG recording.

For continued enrollment into Treatment Period 1, this will be confirmed by continuous 24-hour EEG performed during the 28-day screening period.

9. The subject is willing and able to comply with the study requirements

Exclusion Criteria

1. Unwilling or inability to follow the procedures specified by the protocol
2. Pregnant or breast-feeding
3. Women of child-bearing potential and men who are unable or unwilling to take adequate contraceptive precautions, including one of the following:
o Hormonal contraception (birth control pills, injected hormones or vaginal ring)
o Intrauterine device
o Barrier methods (condom or diaphragm) combined with spermicide
o Surgical sterilization (hysterectomy, tubal ligation, or vasectomy)
4. Current treatment for another significant medical disorder, such as diabetes, heart disease or an untreated disorder, that is discovered during the 28-day screening period and might interfere with the study in the opinion of the Principal Investigator
5. An abnormality on clinical laboratory tests, physical examination, EEG or ECG that might increase the risks associated with trial participation or investigational product administration, such as hepatic enzyme elevation greater than twice normal and/or a GFR < 60 mL/min/1.73 m2
6. History (within last month) of illicit drug use or alcohol dependence, and a commitment not to take illicit drugs during the study
7. Concomitant treatment with more than four (4) AEDs
8. Evidence for a potentially progressive neurologic disorder, such as a brain tumor, multiple sclerosis or dementia
9. Planned epilepsy surgery within six months of enrollment

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
A change in seizure frequency and activity assessed using a patient diary and continuous 24-hour EEG monitoring (composite outcome)[•Seizure Frequency: will be assessed daily by the patient using patient diary.<br> • Seizure Activity will be assessed by Continuous 24-Hour EEG Monitoring during the screening period and on days 1, 8, 15, 22, 28, 43, 50, 57, 64 and 70.<br>]